BLT1 antagonist LSN2792613 reduces infarct size in a mouse model of myocardial ischaemia-reperfusion injury

Cardiovascular Research

Volumn 108, Issue 3, 2015, Pages 367-376

  De Hoog, Vince C ^a   Bovens, Sandra M ^a   De Jager, Saskia C A ^a   Van Middelaar, Ben J ^a   Van Duijvenvoorde, Amerik ^a   Doevendans, Pieter A ^a   Pasterkamp, Gerard ^a   De Kleijn, Dominique P V ^a,b,c   Timmers, Leo ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

BLT1; Ischaemia reperfusion; Leukotriene; LTB4; Myocardial infarction

Indexed keywords

CHEMOATTRACTANT; COLLAGEN; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 6; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LSN 2792613; PROTEIN BLT1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CARDIOTONIC AGENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 ALPHA; GLYCOGEN SYNTHASE KINASE 3 BETA; INTERLEUKIN 8; INTERLEUKIN-6, MOUSE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LTB4R1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HEART EJECTION FRACTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; KERATINOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIAC MUSCLE CELL; CELL PROTECTION; DISEASE MODEL; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CARDIOTONIC AGENTS; COLLAGEN; CYTOPROTECTION; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN-6; INTERLEUKIN-8; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKOTRIENE ANTAGONISTS; MALE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NECROSIS; PHOSPHORYLATION; RECEPTORS, LEUKOTRIENE B4; SIGNAL TRANSDUCTION; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84950315439     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv224     Document Type: Article

References (50)

1. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619.
2. Fox KAA, Steg PG, Eagle KA, Goodman SG, Anderson FA, Granger CB, Flather MD, Budaj A, Quill A, Gore JM. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892-1900.
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
4. Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013;34:1714-1722.
5. Bernink FJP, Timmers L, Beek AM, Diamant M, Roos ST, Van Rossum AC, Appelman Y. Progression in attenuating myocardial reperfusion injury: an overview. Int J Cardiol 2014; 170:261-269.
6. Timmers L, Pasterkamp G, De Hoog VC, Arslan F, Appelman Y, De Kleijn DPV. The innate immune response in reperfused myocardium. Cardiovasc Res 2012;94:276-283.
7. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
8. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
9. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013;123:92-100.
10. Spite M, Hellmann J, Tang Y, Mathis SP, Kosuri M, Bhatnagar A, Jala VR, Haribabu B. Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J Immunol 2011;187:1942-1949.
11. Li RC, Haribabu B, Mathis SP, Kim J, Gozal D. Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis. Am J Respir Crit Care Med 2011;184: 124-131.
12. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007;357:1841-1854.
13. Poeckel D, Funk CD. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res 2010;86:243-253.
14. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-1875.
15. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B 4 receptors. PLEFA 2003;69: 123-134.
16. Williams FM. Neutrophils and myocardial reperfusion injury. Pharmacol Ther 1996;72: 1-12.
17. Daglar G, Karaca T, Yuksek YN, Gozalan U, Akbiyik F, Sokmensuer C, Gurel B, Kama NA. Effect of montelukast and MK-886 on hepatic ischemia-reperfusion injury in rats. J Surg Res 2009;153:31-38.
18. Takeichi T. Effect of ONO-4057 and tacrolimus on ischemia-reperfusion injury of the liver. World J Gastroenterol 2009;15:5712-5715.
19. Ohkubo H, Ito Y, Minamino T, Mishima T, Hirata M, Hosono K, Shibuya M, Yokomizo T, Shimizu T,Watanabe M, Majima M. Leukotriene B4 type-1 receptor signaling promotes liver repair after hepatic ischemia/reperfusion injury through the enhancement of macrophage recruitment. FASEB J 2013;27:3132-3143.
20. Sener G, Sehirli O, Veliog?lu-Og?ünç A, Cetinel S, Gedik N, Caner M, Sakarcan A, Yeg?en BC. Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res 2006;54:65-71.
21. Patel NSA, Cuzzocrea S, Chatterjee PK, Di Paola R, Sautebin L, Britti D, Thiemermann C. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol 2004;66: 220-227.
22. Elshazly SM, Abd El Motteleb DM, Nassar NN. The selective 5-LOX inhibitor 11-keto-b-boswellic acid protects against myocardial ischemia reperfusion injury in rats: involvement of redox and inflammatory cascades. Naunyn Schmiedebergs Arch Pharmacol 2013;386:823-833.
23. Adamek A, Jung S, Dienesch C, Laser M, Ertl G, Bauersachs J, Frantz S. Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice. Eur J Pharmacol 2007;571:51-54.
24. Hahn R, MacDonald B, Simpson P, Potts B, Parli J. Antagonism of leukotriene B4 receptors does not limit canine myocardial infarct size. J Pharmacol Exp Ther 1990;253:58-66.
25. Sasaki K, Ueno A, Kawamura M, Katori M, Shigehiro S, Kikawada R. Reduction of myocardial infarct size in rats by a selective 5-lipoxigenase inhibitor (AA-861). Adv Prostaglandin Thromboxane Leukot Res 1987;17A:381-383.
26. Amsterdam EA, Pan H, Rendig SV, Symons JD, Fletcher MP, Longhurst JC. Limitation of myocardial infarct size in pigs with a dual lipoxygenase-cyclooxygenase blocking agent by inhibition of neutrophil activity without reduction of neutrophil migration. J Am Coll Cardiol 1993;22:1738-1744.
27. Blömer N, Pachel C, Hofmann U, Nordbeck P, Bauer W, Mathes D, Frey A, Bayer B, Vogel B, Ertl G, Bauersachs J, Frantz S. 5-Lipoxygenase facilitates healing after myocardial infarction. Basic Res Cardiol 2013;108:367-376.
28. Bolli R, Becker L, Gross G, Mentzer R, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004;95:125-134.
29. Lonborg J, Schoos MM, Kelbaek H, Holmvang L, Steinmetz J, Veijstrup N, Jorgensen E, Helqvist S, Saunamaki K, Botker HE, Kim WY, Terkelsen CJ, Clemmensen P, Engstrom T. Impact of system delay on infarct size, myocardial salvage index, and left ventricular function in patients with ST-segment elevation myocardial infarction. Am Heart J 2012;164:538-546.
30. Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, Jorgensen E, Helqvist S, Saunamaki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Kober L, Treiman M, Holst JJ, Engstrom T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33: 1491-1499.
31. De Hoog VC, Timmers L, Van Duijvenvoorde A, De Jager SCA, Van Middelaar BJ, Smeets MB, Woodruff TM, Doevendans PA, Pasterkamp G, Hack CE, De Kleijn DPV. Leucocyte expression of complement C5a receptors exacerbates infarct size after myocardial reperfusion injury. Cardiovasc Res 2014;103:521-529.
32. Arslan F, Houtgraaf JH, Keogh B, Kazemi K, De Jong R, McCormack WJ, O'Neill LAJ, McGuirk P, Timmers L, Smeets MB, Akeroyd L, Reilly M, Pasterkamp G, De Kleijn DPV. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv 2012;5: 279-287.
33. Arslan F, Smeets MB, O'Neill LAJ, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, De Kleijn DPV. Myocardial ischemia/reperfusion injury is mediated by leukocytic Toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010;121: 80-90.
34. Sawa Y, Ichikawa H, Kagisaki K, Ohata T, Matsuda H. Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium. J Thorac Cardiovasc Surg 1998;116:511-517.
35. Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH, Entman ML. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999;99:546-551.
36. Sánchez-Galán E, Gómez-Hernández A, Vidal C, Martín-Ventura JL, Blanco-Colio LM, Mun?oz-Garc?á B, Ortega L, Egido J, Tun?ón J. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res 2009;81:216-225.
37. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. Hepatology 1998;27:1172-1177.
38. Frangogiannis NG. Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm Res 2004;53:585-595.
39. Timmers L, Van Keulen JK, Hoefer IE, Meijs MFL, Van Middelaar B, den Ouden K, Van Echteld CJA, Pasterkamp G, De Kleijn DPV. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ Res 2009;104:699-706.
40. Timmers L, Sluijter JPG, Van Keulen JK, Hoefer IE, Nederhoff MGJ, Goumans M-J, Doevendans PA, Van Echteld CJA, Joles JA, Quax PH, Piek JJ, Pasterkamp G, De Kleijn DPV. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 2008;102:257-264.
41. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008;58: 88-111.
42. Beurel E, Jope R. The paradoxical pro-and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006;79:173-189.
43. Ha T, Hu Y, Liu L, Lu C, McMullen JR, Kelley J, Kao RL, Williams DL, Gao X, Li C. TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc Res 2010;87:694-703.
44. Salim T, Sand-Dejmek J, Sjölander A. The inflammatory mediator leukotriene D? induces subcellular b-catenin translocation and migration of colon cancer cells. Exp Cell Res 2014;321:255-266.
45. Dhanasekaran D, Reddy E. JNK signaling in apoptosis. Oncogene 2011;27:6245-6251.
46. Yu C, Minemoto Y, Zhang J, Liu J, Tang F, Bui TN, Xiang J, Lin A. JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 2004; 13:329-340.
47. Engelbrecht A-M, Niesler C, Page C, Lochner A. p38 and JNK have distinct regulatory functions on the development of apoptosis during simulated ischaemia and reperfusion in neonatal cardiomyocytes. Basic Res Cardiol 2004;99:338-350.
48. Timmers L, Sluijter JPG, Verlaan CWJ, Steendijk P, Cramer MJ, Emons M, Strijder C, Gründeman PF, Sze SK, Hua L, Piek JJ, Borst C, Pasterkamp G, De Kleijn DPV. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007;115: 326-332.
49. Hammerman H, Kloner RA, Schoen FJ, Brown EJ, Hale S, Braunwald E. Indomethacin-induced scar thinning after experimental myocardial infarction. Circulation 1983;67:1290-1295.
50. Brown EJ, Kloner RA, Schoen FJ, Hammerman H, Hale S, Braunwald E. Scar thinning due to ibuprofen administration after experimental myocardial infarction. Am J Cardiol 1983; 51:877-883.